Gene therapy for prostate cancer

Expert Review of Anticancer Therapy

Volumn 2, Issue 3, 2002, Pages 309-321

  Gdor, Yehoshua ^a   Timme, Terry L ^a   Miles, Brian J ^a   Kadmon, Dov ^a   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adenovirus; Gene therapy; HSV tk; IL 12; Immunotherapy; Metastasis; Prostate cancer

Indexed keywords

ADENOVIRUS VECTOR; BRCA1 PROTEIN; CASPASE 3; CASPASE 7; CASPASE 9; CELL ADHESION MOLECULE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOSINE DEAMINASE; CYTOTOXIC AGENT; FLUCYTOSINE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 2; LIPOSOME; MYC PROTEIN; NAKED DNA; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE KINASE; RAF PROTEIN; RETINOBLASTOMA PROTEIN; RETROVIRUS VECTOR; UNINDEXED DRUG; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADVANCED CANCER; ANIMAL CELL; ANIMAL MODEL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; GENE DELIVERY SYSTEM; GENE GUN; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE C MYC; PHYDE GENE; POXVIRUS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

EID: 0036081075     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.3.309     Document Type: Review

References (99)

1. Cancer statistics, 2001
2. In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound
3. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice
4. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors
5. Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology
6. Viral vectors for gene therapy
7. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors
8. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
9. Lentiviral vectors approach the clinic but fall back: National Institutes of Health Recombinant DNA Advisory Committee review of a first clinical protocol for use of a lentiviral vector
10. Prostate-specific targeting using PSA promoter-based lentiviral vectors
11. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
12. The addition of adenovirus Type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
13. Evaluation of the biodistribution, persistence, toxicity and potential of germline transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse
14. A Phase I study of the intraprostatic injections of CN706, a prostate-specific antigen gene-regulated cytolytic adenovirus, in patients with locally recurrent cancer following definitive radiotherapy
15. Phase I study of intraprostatic administration of a replication-competent, oncolytic adenovirus using various vector formulations to patients with localized prostate cancer prior to radical prostatectomy
16. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy
17. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung
18. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
19. Adeno-associated virus: Integration at a specific chromosomal locus
20. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer
21. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
22. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a Phase I trial
23. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus Type 1, inoculated intraprostatically in mice and nonhuman primates
24. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
25. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
26. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation
27. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas
28. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
29. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice
30. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant
31. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth
32. In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors
33. Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics
34. Liposome-mediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells
35. Prostate-specific targeting using PSA promoter-based lentiviral vectors
36. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells
37. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer
38. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter
39. The role of p53 in prostate cancer progression
40. p53, the cellular gatekeeper for growth and division
41. Regulation of p53 downstream genes
42. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
43. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells
44. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model
45. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers
46. Clinical evaluation of adenoviral-mediated p53 gene transfer: Review of INGN 201 studies
47. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas
48. A recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene inhibits human tumor cell growth
49. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein
50. Cyclin dependent kinase inhibitors
51. Comparisons of tumor suppressor p53, p21 and p16 gene therapy effects on glioblastoma tumorigenicity in situ
52. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
53. Deletional, mutational and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer
54. Adenovirus p16 gene therapy for prostate cancer
55. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence
56. Role of adhesion molecules in bladder cancer, an important part of the jigsaw
57. Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer
58. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model
59. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde
60. The DNA damage response: Putting checkpoints in perspective
61. BRCA1 and prostate cancer
62. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability
63. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
64. The Bcl-2 protein family, arbiters of cell survival
65. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer
66. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-α (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: Relationship to the decreased viability of T24 prostate cancer cells
67. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice
68. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: A novel therapy in prostate cancer
69. Antisense c-myc retroviral vector suppresses established human prostate cancer
70. Adenovirus-mediated transfer of inducible caspases: A novel 'death switch' gene therapeutic approach to prostate cancer
71. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
72. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer
73. Fusogenic membrane glycoproteins as a novel class of genes for the local, immune-mediated control of tumor growth
74. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: Implications for gene therapy
75. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas
76. Prodrug-activating systems in suicide gene therapy
77. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
78. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models
79. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer
80. Cooperative therapeutic effects of androgen ablation and adenovirus- mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer
81. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: Changes in tumour cell proliferative activity
82. In situ gene therapy for adenocarcinoma of the prostate: A Phase I clinical trial
83. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme
84. Cytopathic effect of in situ gene therapy in prostate cancer
85. Prodrug activation gene therapy, external beam irradiation in the treatment of prostate cancer
86. Enhanced therapeutic effect of HSV-tk+GCV gene therapy, ionizing radiation for prostate cancer
87. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer
88. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
89. Phase I study of Ad-OC-TK plus valacyclovir for the treatment of metastatic or recurrent prostate cancer
90. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene and radiotherapy
91. Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation
92. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity
93. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity
94. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
95. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: Immunogene therapy using a highly secreTable form of interleukin-15 gene transfer
96. Prostate cancer gene therapy: Comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines
97. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
98. Demonstration of a rational strategy for human prostate cancer gene therapy
99. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor transfer